17 completed, 4 unknown, 2 not yet recruiting, 1 withdrawn. 9 Phase 2, 9 Phase 3, 5 Phase 4, 1 Not applicable, 1 Phase 1.
Follow Chronic Idiopathic Urticaria: new trials by email Literature Review of Chronic Idiopathic Urticaria trials Research Report on Chronic Idiopathic Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU) THB335 Lower Dose, THB335 Higher Dose, Placebo - Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria | Phase 2 | Not yet recruiting | Calixis Inc. | 81 | 2026-09-01 | 2026-08-17 |
| Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. Autologous whole blood therapy, Desloratadine - Chronic Idiopathic Urticaria | Phase 3 | Not yet recruiting | Cairo University | 40 | 2026-04-30 | 2026-03-20 |
| Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria UB-221 - Chronic Idiopathic Urticaria | Phase 1 | Unknown | United BioPharma | 32 | 2023-12-30 | 2022-10-03 |
| Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria Omalizumab Injection, Xolair Prefilled Syringe - Chronic Idiopathic Urticaria | Phase 3 | Completed | Kashiv BioSciences, LLC | 600 | 2023-08-15 | 2025-02-05 |
| Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Povorcitinib, Placebo - Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Completed | Incyte Corporation | 136 | 2023-07-31 | 2026-03-12 |
| A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases KPL-716, Placebo - Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus | Phase 2 | Completed | Genentech, Inc. | 58 | 2019-05-29 | 2025-03-18 |
| Mast Cell Activation Test in Allergic Disease Asthma, Mastocytosis | Completed | Hong Kong Sanatorium & Hospital | 19 | 2018-02-01 | 2020-04-09 | |
| Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody benralizumab, placebo - Chronic Idiopathic Urticaria | Phase 4 | Completed | Jonathan A. Bernstein, MD | 12 | 2017-09-12 | 2019-07-10 |
| Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria Xolair - Chronic Idiopathic Urticaria | Not applicable | Completed | Asthma Inc Clinical Research Center | 20 | 2016-09-01 | 2019-01-24 |
| Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Omalizimab - Chronic Idiopathic Urticaria | Phase 3 | Unknown | Rabin Medical Center | 20 | 2014-07-01 | 2014-06-18 |
| Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines AZD1981, Placebo - Chronic Idiopathic Urticaria | Phase 2 | Completed | Johns Hopkins University | 38 | 2014-01-01 | 2017-07-12 |
| Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Omalizumab (Xolair), Placebo - Chronic Urticaria, Chronic Idiopathic Urticaria | Phase 2 / Phase 3 | Completed | Insel Gruppe AG, University Hospital Bern | 30 | 2012-09-01 | 2014-04-15 |
| Efficacy Study of Canakinumab to Treat Urticaria Canakinumab, Placebo - Chronic Idiopathic Urticaria | Phase 2 | Unknown | University of Zurich | 20 | 2012-06-01 | 2016-09-27 |
| Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment IGE025, placebo - Chronic Idiopathic Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2012-04-01 | 2015-03-31 |
| A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) Placebo, Omalizumab - Chronic Idiopathic Urticaria | Phase 3 | Completed | Genentech, Inc. | 323 | 2011-03-01 | 2013-10-11 |
| A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist - Chronic Idiopathic Urticaria | Phase 3 | Completed | Genentech, Inc. | 336 | 2011-02-01 | 2013-11-26 |
| A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment Omalizumab, Placebo - Chronic Idiopathic Urticaria | Phase 3 | Completed | Genentech, Inc. | 319 | 2011-02-01 | 2013-11-27 |
| Etanercept for the Treatment of Chronic Urticaria etanercept, placebo - Chronic Idiopathic Urticaria | Phase 2 / Phase 3 | Withdrawn | University of Utah | 2010-12-01 | 2015-06-02 | |
| A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) omalizumab, placebo, H1 antihistamines - Chronic Idiopathic Urticaria | Phase 2 | Completed | Genentech, Inc. | 90 | 2009-03-01 | 2017-07-11 |
| Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) 5-mg Desloratadine, 10-mg Desloratadine, 20-mg Desloratadine - Chronic Idiopathic Urticaria | Phase 4 | Completed | Organon and Co | 314 | 2007-09-01 | 2024-05-23 |
Showing 20 of 24. Sign in to see all of them.
Chronic Urticaria (24) · Urticaria (5) · Pruritus (2) · Anaphylaxis (1) · Angioedema (1) · Asthma (1) · Eczema (1) · Food Hypersensitivity (1) · Hypersensitivity (1) · Lichen Planus (1) · Mast Cell Activation Syndrome (1) · Mastocytosis (1) · Neurodermatitis (1)
Chronic Disease (24) · Disease Attributes (24) · Hypersensitivity, Immediate (24) · Immune System Diseases (24) · Pathologic Processes (24) · Pathological Conditions, Signs and Symptoms (24) · Skin Diseases (24) · Skin Diseases, Vascular (24) · Skin and Connective Tissue Diseases (24) · Hypersensitivity (23) · Urticaria (19) · Dermatitis (2) · Signs and Symptoms (2) · Skin Diseases, Eczematous (2) · Skin Manifestations (2)
Omalizumab (9) · desloratadine (5) · Diphenhydramine (2) · levocetirizine (2) · AZD1981 (1) · Etanercept (1) · Histamine Antagonists (1) · Leukotriene Antagonists (1) · benralizumab (1) · canakinumab (1)
Genentech, Inc. (5) · Organon and Co (3) · Asthma Inc Clinical Research Center (1) · Cairo University (1) · Calixis Inc. (1) · Hong Kong Sanatorium & Hospital (1) · Incyte Corporation (1) · Insel Gruppe AG, University Hospital Bern (1) · Johns Hopkins University (1) · Jonathan A. Bernstein, MD (1) · Kashiv BioSciences, LLC (1) · Lotus Pharmaceutical (1) · Novartis Pharmaceuticals (1) · Rabin Medical Center (1) · UCB Pharma (1)
United States (10) · Germany (6) · Poland (4) · France (3) · Italy (3) · Spain (3) · Switzerland (3) · Denmark (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Egypt (1) · Hong Kong (1) · India (1)
Christopher Hull, MD (1) · Edward R. Conner, M.D. (1) · Jia-Yu Chu (1) · Karin Rosen, M.D., Ph.D. (1) · Michael David, Prof (1) · Oliver Hausmann (1) · Peter Schmid-Grendelmeier, Prof MD (1) · Sarbjit S Saini, MD (1) · Tak H Lee (1) · William Henderson, MD (1)
PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 39193419, PMID 19133920, PMID 23432142, PMID 25046337, PMID 29974963, PMID 32827729, PMID 41847564